Dyskinesias: Clinical Trials

142 trials for Dyskinesias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

77 completed, 18 unknown, 16 recruiting, 13 terminated. 142 Phase 1, 49 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1142Completed 77, Unknown 18, Recruiting 16, Terminated 13, Active not recruiting 7, Not yet recruiting 6, Withdrawn 5
Phase 249Completed 23, Recruiting 8, Active not recruiting 5, Terminated 5, Unknown 4, Not yet recruiting 3, Withdrawn 1

Follow Dyskinesias: new trials by email Literature Review of Dyskinesias trials Research Report on Dyskinesias

Trials (filtered) newest first · largest first

All 142 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep
Ferrous Sulfate, Placebo - ADHD, Sleep Problems
Phase 1 / Phase 2Not yet recruitingHugo W. Moser Research Institute at Kennedy Krieger, Inc.702027-03-012026-05-04
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
IMM02-KORA - Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
Phase 1Not yet recruitingImmunis, Inc.152026-11-302026-10-30
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg - Healthy Adult Participants
Phase 1Not yet recruitingNeurelis, Inc.242026-10-162026-11-06
Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Antisense oligonucleotide targeting the ATM gene - Ataxia Telangiectasia
Phase 1 / Phase 2RecruitingTimothy Yu102026-08-012026-05-28
Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy
Intrathecal infusion, Intranasal infusion - Spinocerebellar Ataxia - All Sub-types
Phase 1 / Phase 2Not yet recruitingBiocells Medical902026-06-012026-03-12
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
SRP-1005, Placebo - Huntington's Disease
Phase 1RecruitingSarepta Therapeutics, Inc.322026-05-122026-10-19
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
[14C] LPM3770164 - Huntington Disease
Phase 1Not yet recruitingLuye Pharma Group Ltd.82026-04-302026-04-08
Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease
hNSC-01 - Huntington Disease
Phase 1 / Phase 2RecruitingLeslie Thompson212026-04-062026-04-13
Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor
Deep Brain Stimulation - Tremor, Essential Tremor
Phase 1RecruitingThe Cleveland Clinic122026-01-152026-07-10
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
Transcranial Electrical Stimulation Device - PARKINSON DISEASE (Disorder)
Phase 1 / Phase 2RecruitingU: The Mind Company302026-01-012026-01-27
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
ALN-SNCA, Placebo - Parkinsons Disease
Phase 1RecruitingRegeneron Pharmaceuticals462025-12-052026-09-21
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1 / Phase 2RecruitingBeijing Tide Pharmaceutical Co., Ltd2662025-12-032026-01-28
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
RG6496, Placebo - Huntington's Disease
Phase 1Active not recruitingHoffmann-La Roche32025-11-192026-09-02
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
SGT-212 - Friedreich's Ataxia (FA)
Phase 1RecruitingSolid Biosciences Inc.102025-10-222026-11-06
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.
Antisense oligonucleotide treatment (ASO) - GNAO1, Epilepsy
Phase 1 / Phase 2RecruitingPirogov Russian National Research Medical University52025-09-092026-01-23
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
SPK-10001, Placebo Surgery Control - Huntington Disease
Phase 1 / Phase 2RecruitingHoffmann-La Roche532025-02-212026-05-05
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
ER2001 intravenous injection, Placebo - Huntington Disease
Phase 1 / Phase 2Active not recruitingExoRNA Bioscience272025-02-112026-01-14
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg - Tardive Dyskinesia (TD)
Phase 1 / Phase 2RecruitingLuye Pharma Group Ltd.1202025-01-142025-01-22
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
ARO-ATXN2 Injection, Placebo - Spinocerebellar Ataxia Type 2
Phase 1Active not recruitingArrowhead Pharmaceuticals392024-12-172026-06-29

Showing 20 of 142. Sign in to see all of them.

Narrower conditions

Huntington Disease (57)  ·  Parkinson Disease (17)  ·  Movement Disorders (13)  ·  Alzheimer Disease (11)  ·  Dystonia (10)  ·  Tremor (10)  ·  Psychomotor Agitation (9)  ·  Ataxia (8)  ·  Tardive Dyskinesia (8)  ·  Torticollis (8)  ·  Essential Tremor (7)  ·  Neurodegenerative Diseases (7)  ·  Chorea (6)  ·  Schizophrenia (6)

Broader conditions

Nervous System Diseases (131)  ·  Central Nervous System Diseases (115)  ·  Neurologic Manifestations (95)  ·  Brain Diseases (94)  ·  Movement Disorders (85)  ·  Pathological Conditions, Signs and Symptoms (84)  ·  Signs and Symptoms (84)  ·  Neurodegenerative Diseases (82)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (75)  ·  Basal Ganglia Diseases (74)  ·  Genetic Diseases, Inborn (72)  ·  Mental Disorders (72)  ·  Heredodegenerative Disorders, Nervous System (69)  ·  Neurocognitive Disorders (62)

Interventions

latrepirdine (8)  ·  Botulinum Toxins, Type A (4)  ·  6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (3)  ·  Dexmedetomidine (3)  ·  Sugars (3)  ·  1-Octanol (2)  ·  5-(5-((2,4-dimethylthiazol-5-yl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo(3,4-b)pyridin-4-amine (2)  ·  Deep Brain Stimulation (2)  ·  Olanzapine (2)  ·  Risperidone (2)  ·  deutetrabenazine (2)  ·  octanoic acid (2)  ·  7-(2-(4-(2-fluoro-4-iodophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine (1)  ·  Alprazolam (1)  ·  Ampicillin (1)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (10)  ·  Pfizer (9)  ·  Luye Pharma Group Ltd. (5)  ·  Wave Life Sciences USA, Inc. (5)  ·  Hoffmann-La Roche (4)  ·  Oregon Health and Science University (4)  ·  BioXcel Therapeutics Inc (3)  ·  Siena Biotech S.p.A. (3)  ·  Yale University (3)  ·  Chaitanya Hospital, Pune (2)  ·  GlaxoSmithKline (2)  ·  Institute for Neurodegenerative Disorders (2)  ·  Teachers College, Columbia University (2)  ·  UniQure Biopharma B.V. (2)  ·  University of British Columbia (2)

Countries

United States (80)  ·  United Kingdom (19)  ·  Canada (18)  ·  Germany (16)  ·  Australia (10)  ·  France (9)  ·  China (8)  ·  Poland (7)  ·  Denmark (6)  ·  Netherlands (6)  ·  Spain (5)  ·  New Zealand (3)  ·  South Korea (3)  ·  Switzerland (3)  ·  Brazil (2)

Top investigators

BioXcel MM, MD (3)  ·  David Russell, MD (2)  ·  Mark Hallett, M.D. (2)  ·  Alan Hand, MD (1)  ·  Alison E Pritchard, PhD (1)  ·  Anne Chiaramello, Ph.D. (1)  ·  Barry Oken, MD (1)  ·  Bernhard G Landwehrmeyer, MD, PhD (1)

Results publications

PMID 29480210, PMID 32250312, PMID 36463457, PMID 38489195, PMID 10816186, PMID 12112073, PMID 14718713, PMID 15210907, PMID 16324089, PMID 18794494, PMID 19838774, PMID 20065126, PMID 20213818, PMID 20606544, PMID 21211990, PMID 21594724, PMID 22454323, PMID 23408867, PMID 24878825, PMID 25037310, PMID 25223836, PMID 26927672, PMID 27072954, PMID 27434297, PMID 29725840, PMID 30095337, PMID 31059641, PMID 31356217, PMID 31381524, PMID 32609960, PMID 34185708, PMID 36280451, PMID 37171121, PMID 38058356, PMID 38615323, PMID 38988035, PMID 39027419, PMID 39775041, PMID 40034447, PMID 40235521, PMID 40739200, PMID 41171420, PMID 41188963, PMID 42032152, PMID 42307907

NIH funding

2015 (3), 2025 (2), 2014 (1), 2016 (1), 2018 (1), R01MH059101 (1), R03DC012429 (1), R21DK113487 (1), R61HL151355 (1), UH3TR003897 (1)